Journalartikel - Wissenschaftlicher Artikel | 2023

HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG : (Status Quo and Quo Vadis)

Autor*innen

Fisenkci, N. ; Böhler, Yvonne-Beatrice

Zeitschrift

Value in health

DOI

10.1016/j.jval.2023.09.1921

Weitere Details

Sprache

englisch

Darstellungsform

Text

Band

Ausgabe

Seitenbereich

365 - 366

Zitierstile

Fisenkci, N., & Böhler, Y.-B. (2023). HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG. Value in Health, 26(12), 365–366. doi:10.1016/j.jval.2023.09.1921

In die Zwischenablage kopieren

Fisenkci, N. and Böhler, Y.-B., 2023. HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG. Value in health, 26(12), pp.365–366.

In die Zwischenablage kopieren

Fisenkci, N. & Böhler, Yvonne-Beatrice 2023. HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG. Value in health 26, 12, 365–366.

In die Zwischenablage kopieren

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format

Zitierstile

In die Zwischenablage kopieren

Fisenkci, N. and Böhler, Y.-B., 2023. HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG. Value in health, 26(12), pp.365–366.

In die Zwischenablage kopieren

Fisenkci, N. & Böhler, Yvonne-Beatrice 2023. HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG. Value in health 26, 12, 365–366.

In die Zwischenablage kopieren

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format

American Psychological Association 6th edition (DOI)

Anglia Ruskin University - Harvard

Gesellschaft für Bildung und Forschung in Europa - Harvard